Boston Scientific (NYSE:BSX) Stock Purchased Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Boston Scientific stock on August 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

Boston Scientific Stock Performance

NYSE:BSX opened at $43.00 on Friday. The company has a market cap of $62.31 billion, a P/E ratio of 17.41, a P/E/G ratio of 1.00 and a beta of 0.57. The firm’s 50 day moving average is $47.00 and its two-hundred day moving average is $54.66. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.29 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently modified their holdings of BSX. BlackRock Inc. acquired a new position in Boston Scientific during the 2nd quarter worth approximately $5,534,781,000. California State Teachers Retirement System raised its stake in shares of Boston Scientific by 4,113.5% during the second quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider’s stock valued at $4,136,078,000 after purchasing an additional 94,609,083 shares during the period. State Street Corp raised its stake in shares of Boston Scientific by 1.4% during the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the period. Primecap Management Co. CA acquired a new position in shares of Boston Scientific during the second quarter worth $2,156,233,000. Finally, Capital World Investors lifted its position in shares of Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BSX shares. Argus reissued a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Citigroup dropped their target price on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Canaccord Genuity Group cut their price target on shares of Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Finally, BTIG Research reduced their price target on shares of Boston Scientific from $60.00 to $56.00 and set a “buy” rating on the stock in a research report on Wednesday. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.46.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger acquired 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.